144 related articles for article (PubMed ID: 36913542)
41. Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials.
Camilli M; Lombardi M; Chiabrando JG; Zito A; Del Buono MG; Vergallo R; Aspromonte N; Lombardo A; Montone RA; Niccoli G; Biondi-Zoccai G; Crea F; Minotti G
Am J Ther; 2021 Nov; 29(2):e199-e204. PubMed ID: 35389572
[TBL] [Abstract][Full Text] [Related]
42. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
[TBL] [Abstract][Full Text] [Related]
43. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB; Røikjer JB; Dal J; Jensen MH
Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
[TBL] [Abstract][Full Text] [Related]
44. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
Sinha B; Ghosal S
Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
[TBL] [Abstract][Full Text] [Related]
45. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
46. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V
Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040
[TBL] [Abstract][Full Text] [Related]
47. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
[TBL] [Abstract][Full Text] [Related]
48. Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents.
Chen YW; Voelker J; Tunceli O; Pericone CD; Bookhart B; Durkin M
J Med Econ; 2020 Apr; 23(4):401-406. PubMed ID: 31801393
[No Abstract] [Full Text] [Related]
49. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
50. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
[TBL] [Abstract][Full Text] [Related]
51. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
[TBL] [Abstract][Full Text] [Related]
52. Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study.
Ena J; Carretero-Gómez J; Zapatero-Gaviria A; Carrasco-Sánchez FJ; Del Romero-Sánchez M; González-Becerra C; Blazquez-Encinar JC; Iguzquiza-Pellejero MJ; de Escalante Yangüela B; Gómez-Huelgas R;
Rev Clin Esp (Barc); 2021 Nov; 221(9):517-528. PubMed ID: 34752263
[TBL] [Abstract][Full Text] [Related]
53. The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.
Ali MU; Mancini GBJ; Fitzpatrick-Lewis D; Lewis R; Jovkovic M; Zieroth S; O'Meara E; Connelly KA; Sherifali D
Can J Cardiol; 2022 Aug; 38(8):1201-1210. PubMed ID: 35961756
[TBL] [Abstract][Full Text] [Related]
54. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
55. Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Correale M; Petroni R; Coiro S; Antohi EL; Monitillo F; Leone M; Triggiani M; Ishihara S; Dungen HD; Sarwar CMS; Memo M; Sabbah HN; Metra M; Butler J; Nodari S
Heart Fail Rev; 2022 Jul; 27(4):1147-1163. PubMed ID: 34097173
[TBL] [Abstract][Full Text] [Related]
56. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
57. Disparities in adoption of new diabetic therapies with cardiovascular benefits.
Vasti EC; Basina M; Calma J; Maron DJ; Rodriguez F; Sandhu AT
Diabetes Res Clin Pract; 2023 Feb; 196():110233. PubMed ID: 36581144
[TBL] [Abstract][Full Text] [Related]
58. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
[TBL] [Abstract][Full Text] [Related]
60. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
